Coronavirus
Pfizer and BioNTech Will Test an Omicron Vaccine on Adults
Pfizer and BioNTech announced on Tuesday that the companies will start a human trial to evaluate the efficacy, safety, and tolerability of a vaccine specifically modified to target the omicron variant of COVID-19.
“Vaccines continue to offer strong protection against severe disease caused by Omicron. Yet, emerging data indicate vaccine-induced protection against infection and mild to moderate disease wanes more rapidly than was observed with prior strains,” Ugur Sahin, CEO and co-founder of BioNTech, said in a statement.
The study will include 1,420 adults in several groups based on their vaccine status.
